Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avantor, Inc.AVTR · Entity 3546 | Director | May 08, 2025 | May 12, 2025 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 08, 2023 | June 12, 2023 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Operating Officer | October 05, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avantor, Inc.
Report date May 08, 2025 · Filed May 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,480 |
Reported balance
After 2025-05-08 transaction · row 1
1 source rowRow 1 · 2025-05-08 · Grant · Acquired 17,100 · Balance 65,480 F1: Reflects a grant of restricted stock units that vests on May 08, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 08, 2026.
Evelo Biosciences, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08 | Direct | 20,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.
Moderna, Inc.
Report date October 05, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 125,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2020 Filed May 14, 2020 21:02 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 127,500 | $12.21 | $1,556,775.00 |
DisclosureSEC source: 0001127602-20-016625 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 13, 2020 Filed Jun 4, 2020 22:41 UTC Amendment | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,300 | $66.89 | $86,957.00 |
DisclosureSEC source: 0001127602-20-018895 · form4a.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.88 to $66.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-015199 · form4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812,322 Underlying: Common Stock · 25,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,934 | $49.69 | $195,480.46 |
DisclosureSEC source: 0001127602-20-015199 · form4.xml · nonDerivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.36 to $50.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,984 | $48.87 | $194,698.08 |
DisclosureSEC source: 0001127602-20-015199 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,934 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.34 to $49.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,784 | $47.82 | $515,690.88 |
DisclosureSEC source: 0001127602-20-015199 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,918 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.33 to $48.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,298 | $46.91 | $295,439.18 |
DisclosureSEC source: 0001127602-20-015199 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,702 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.32 to $47.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:29 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 25,000 | $12.21 | $305,250.00 |
DisclosureSEC source: 0001127602-20-015199 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 01, 2020 Filed Jun 4, 2020 22:43 UTC Amendment | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,934 | $49.69 | $195,480.46 |
DisclosureSEC source: 0001127602-20-018896 · form4a.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.36 to $50.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,403 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-013895 · form4.xml · derivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837,322 Underlying: Common Stock · 23,403 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 9,944 | $37.78 | $375,684.32 |
DisclosureSEC source: 0001127602-20-013895 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.33 to $38.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 8,852 | $36.91 | $326,727.32 |
DisclosureSEC source: 0001127602-20-013895 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,944 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.32 to $37.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 4,607 | $36.04 | $166,036.28 |
DisclosureSEC source: 0001127602-20-013895 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,796 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.31 to $36.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 21:00 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 23,403 | $12.21 | $285,750.63 |
DisclosureSEC source: 0001127602-20-013895 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-013503 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860,725 Underlying: Common Stock · 300 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 300 | $35.13 | $10,539.00 |
DisclosureSEC source: 0001127602-20-013503 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.08 to $35.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:48 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 300 | $12.21 | $3,663.00 |
DisclosureSEC source: 0001127602-20-013503 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 03, 2020 Filed Apr 6, 2020 20:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,697 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-013313 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 861,025 Underlying: Common Stock · 13,697 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| April 03, 2020 Filed Apr 6, 2020 20:07 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 13,697 | $35.09 | $480,627.73 |
DisclosureSEC source: 0001127602-20-013313 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 03, 2020 Filed Apr 6, 2020 20:07 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 13,697 | $12.21 | $167,240.37 |
DisclosureSEC source: 0001127602-20-013313 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,281 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · derivative · entry 9 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874,722 Underlying: Common Stock · 15,281 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 8,187 | $31.75 | $259,937.25 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 7 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.43 to $32.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 7,094 | $31.06 | $220,339.64 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,187 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.40 to $31.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 15,281 | $12.21 | $186,581.01 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,317 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · derivative · entry 8 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,003 Underlying: Common Stock · 16,317 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 730 | $32.50 | $23,725.00 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.42 to $32.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,581 | $31.98 | $178,480.38 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.40 to $32.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,006 | $30.47 | $304,882.82 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,311 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.05 to $30.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 20:50 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 16,317 | $12.21 | $199,230.57 |
DisclosureSEC source: 0001127602-20-011511 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 104 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-010258 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,320 Underlying: Common Stock · 104 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 104 | $30.00 | $3,120.00 |
DisclosureSEC source: 0001127602-20-010258 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 104 | $12.21 | $1,269.84 |
DisclosureSEC source: 0001127602-20-010258 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,001 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-009396 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,424 Underlying: Common Stock · 3,001 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,001 | $30.12 | $90,390.12 |
DisclosureSEC source: 0001127602-20-009396 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 3,001 | $12.21 | $36,642.21 |
DisclosureSEC source: 0001127602-20-009396 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 28,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · derivative · entry 8 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,924 Underlying: Common Stock · 28,924 shares Expires not disclosed F8 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F8 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 161,120 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · derivative · entry 7 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,120 Underlying: Common Stock · 161,120 shares Expires 2030-02-28 F7 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,006 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,425 Underlying: Common Stock · 8,006 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 500 | $31.95 | $15,975.00 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.59 to $32.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,272 | $33.05 | $108,139.60 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.60 to $33.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,188 | $34.10 | $74,610.80 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,772 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.62 to $34.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,046 | $34.81 | $71,221.26 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,960 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.63 to $35.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 8,006 | $12.21 | $97,753.26 |
DisclosureSEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:52 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 11,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-20-000062 · wf-form4_158267113896896.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,951 F1 · kind: Reflects a grant of restricted stock units that vests on February 21, 2021. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 16:07 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 31,380 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001694665-19-000084 · wf-form4_157566641120948.xml · derivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,380 Underlying: Common Stock · 31,380 shares Expires 2029-12-04 F1 · derivative.exercise_date: 1. The option vests in 36 equal monthly installments following the award grant date. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:28 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 3,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-19-000020 · wf-form4_156935691937480.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · kind: Reflects a grant of restricted stock units that vests on September 20, 2020. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 254,396 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-19-010852 · form4.xml · derivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,396 Underlying: Common Stock · 254,396 shares Expires 2029-03-08 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.